Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease
Experts on Alzheimer disease discuss how the introduction of disease-modifying therapies has impacted the treatment landscape.
EP: 1.The Clinical and Economic Implications of Alzheimer Disease Across Patients, Families, and the Health Care System
EP: 2.Recent Insights into the Pathophysiology of Alzheimer Disease
EP: 3.Genetic Aspects of Alzheimer Disease
EP: 4.The Patient Experience: From Symptoms to Diagnosis of Alzheimer Disease
EP: 5.Potential Consequences of Early Diagnosis of Alzheimer Disease
EP: 6.Criteria for Diagnosing Alzheimer Disease and the Role of Testing
EP: 7.Exploring the Economic Impact of Advanced Approaches for Diagnosing Alzheimer Disease
Now Viewing
EP: 8.Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease
EP: 9.Clinical Decision-Making for Alzheimer Disease Management
EP: 10.Cost, Value, and Affordability of Treatment for Alzheimer Disease
EP: 11.Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates
EP: 12.Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden
EP: 13.Payer Coverage Considerations for New Treatments for Alzheimer Disease
EP: 14.Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook
Video content above is prompted by the following question(s):
- What has been the clinical impact and the target patients for the use of anti-amyloid β monoclonal antibodies?
- Aducanumab approved by the FDA in 2021; development and commercialization discontinued on Jan 31, 2024
- Lecanemab approved by the FDA in 2023
Related Content
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Article
Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
